-
1
-
-
84957940642
-
-
Fact Sheet 297
-
WHO. Cancer. Fact Sheet 297. 2006. http://www.who.int/mediacentre/ factsheets/ fs297/en/index.html.
-
(2006)
Cancer
-
-
-
2
-
-
53749097825
-
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials
-
NSCLC Meta-Analyses Collaborative Group
-
NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4617-4625
-
-
-
3
-
-
44249086425
-
Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship
-
DOI 10.4065/83.5.584
-
Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94. (Pubitemid 351720831)
-
(2008)
Mayo Clinic Proceedings
, vol.83
, Issue.5
, pp. 584-594
-
-
Molina, J.R.1
Yang, P.2
Cassivi, S.D.3
Schild, S.E.4
Adjei, A.A.5
-
4
-
-
34447299692
-
EGFR targeting of solid tumors
-
Rocha-Lima CM, Soares HP, Raez LE, et al. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304. (Pubitemid 47057800)
-
(2007)
Cancer Control
, vol.14
, Issue.3
, pp. 295-304
-
-
Rocha-Lima, C.M.1
Soares, H.P.2
Raez, L.E.3
Singal, R.4
-
5
-
-
65349116059
-
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial
-
Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31.
-
(2009)
Lancet
, vol.373
, pp. 1525-1531
-
-
Pirker, R.1
Pereira, J.R.2
Szczesna, A.3
-
6
-
-
77949891126
-
Cetuximab and first-line taxane/ carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099
-
Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/ carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-17.
-
(2010)
J Clin Oncol
, vol.28
, pp. 911-917
-
-
Lynch, T.J.1
Patel, T.2
Dreisbach, L.3
-
8
-
-
0034949214
-
A biological staging model for operable non-small cell lung cancer
-
DOI 10.1136/thorax.56.7.561
-
Cox G, Jones JL, Andi A, et al. A biological staging model for operable non-small cell lung cancer. Thorax 2001;56:561-6. (Pubitemid 32588536)
-
(2001)
Thorax
, vol.56
, Issue.7
, pp. 561-566
-
-
Cox, G.1
Jones, J.L.2
Andi, A.3
Waller, D.A.4
O'Byrne, K.J.5
-
9
-
-
61549118453
-
Targeted therapies in lung cancer
-
Pirker R, Filipits M. Targeted therapies in lung cancer. Curr Pharm Des 2009;15:188-206.
-
(2009)
Curr Pharm des
, vol.15
, pp. 188-206
-
-
Pirker, R.1
Filipits, M.2
-
10
-
-
41149169801
-
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry
-
DOI 10.2353/jmoldx.2008.070125
-
Pinter F, Papay J, Almasi A, et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn 2008;10:160-8. (Pubitemid 351428398)
-
(2008)
Journal of Molecular Diagnostics
, vol.10
, Issue.2
, pp. 160-168
-
-
Pinter, F.1
Papay, J.2
Almasi, A.3
Sapi, Z.4
Szabo, E.5
Kanya, M.6
Tamasi, A.7
Jori, B.8
Varkondi, E.9
Moldvay, J.10
Szondy, K.11
Keri, G.12
Dominici, M.13
Conte, P.14
Eckhardt, S.15
Kopper, L.16
Schwab, R.17
Petak, I.18
-
11
-
-
68949213744
-
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer
-
Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009;28(Suppl 1): S32-7.
-
(2009)
Oncogene
, vol.28
, Issue.SUPPL. 1
-
-
Hirsch, F.R.1
Varella-Garcia, M.2
Cappuzzo, F.3
-
12
-
-
5644296647
-
Gefitinib ('Iressa,' ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: Tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone
-
Bailey R, Kris M, Wolf M, et al. Gefitinib ('Iressa,' ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Canc 2003;41(Suppl 2):S71.
-
(2003)
Lung Canc
, vol.41
, Issue.SUPPL. 2
-
-
Bailey, R.1
Kris, M.2
Wolf, M.3
-
13
-
-
0043132288
-
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC
-
DOI 10.1200/JCO.2003.01.039
-
Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:2658-63. (Pubitemid 46606308)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.14
, pp. 2658-2663
-
-
Cappuzzo, F.1
Gregorc, V.2
Rossi, E.3
Cancellieri, A.4
Magrini, E.5
Paties, C.T.6
Ceresoli, G.7
Lombardo, L.8
Bartolini, S.9
Calandri, C.10
De Rosa, M.11
Villa, E.12
Crino, L.13
-
14
-
-
3843116718
-
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
-
Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in nonsmall- cell lung cancer. Br J Cancer 2004;91:208-12. (Pubitemid 39037060)
-
(2004)
British Journal of Cancer
, vol.91
, Issue.2
, pp. 208-212
-
-
Parra, H.S.1
Cavina, R.2
Latteri, F.3
Zucali, P.A.4
Campagnoli, E.5
Morenghi, E.6
Grimaldi, G.C.7
Roncalli, M.8
Santoro, A.9
-
15
-
-
2342471392
-
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib
-
DOI 10.1056/NEJMoa040938
-
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.21
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
16
-
-
2342624080
-
EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy
-
DOI 10.1126/science.1099314
-
Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
-
(2004)
Science
, vol.304
, Issue.5676
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
Eck, M.J.14
Sellers, W.R.15
Johnson, B.E.16
Meyerson, M.17
-
17
-
-
4644274700
-
Mutations and addiction to EGFR: The Achilles 'heal' of lung cancers?
-
DOI 10.1016/j.molmed.2004.08.008, PII S1471491404002163
-
Gazdar AF, Shigematsu H, Herz J, et al. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 2004;10:481-6. (Pubitemid 39303620)
-
(2004)
Trends in Molecular Medicine
, vol.10
, Issue.10
, pp. 481-486
-
-
Gazdar, A.F.1
Shigematsu, H.2
Herz, J.3
Minna, J.D.4
-
18
-
-
44849093562
-
Oncogene addiction
-
discussion 80
-
Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68:3077-80; discussion 80.
-
(2008)
Cancer Res
, vol.68
, pp. 3077-3080
-
-
Weinstein, I.B.1
Joe, A.2
-
19
-
-
6344278732
-
Inherited predisposition to early onset lung cancer according to histological type
-
DOI 10.1002/ijc.20436
-
Li X, Hemminki K. Inherited predisposition to early onset lung cancer according to histological type. Int J Cancer 2004;112:451-7. (Pubitemid 39390610)
-
(2004)
International Journal of Cancer
, vol.112
, Issue.3
, pp. 451-457
-
-
Xinjun, L.I.1
Hemminki, K.2
-
20
-
-
41049089483
-
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors
-
Regales L, Balak MN, Gong Y, et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2007;2:e810.
-
(2007)
PLoS One
, vol.2
-
-
Regales, L.1
Balak, M.N.2
Gong, Y.3
-
21
-
-
61549108338
-
EGFR T790M mutation: A double role in lung cancer cell survival?
-
Suda K, Onozato R, Yatabe Y, et al. EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 2009;4:1-4.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 1-4
-
-
Suda, K.1
Onozato, R.2
Yatabe, Y.3
-
22
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
DOI 10.1056/NEJMoa044238
-
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of nonsmall- cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92. (Pubitemid 40271173)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.8
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
Janne, P.A.4
Kocher, O.5
Meyerson, M.6
Johnson, B.E.7
Eck, M.J.8
Tenen, D.G.9
Halmos, B.10
-
23
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
-
24
-
-
34250329445
-
EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity
-
DOI 10.1158/0008-5472.CAN-07-0217
-
Vikis H, Sato M, James M, et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 2007;67:4665-70. (Pubitemid 46910171)
-
(2007)
Cancer Research
, vol.67
, Issue.10
, pp. 4665-4670
-
-
Vikis, H.1
Sato, M.2
James, M.3
Wang, D.4
Wang, Y.5
Wang, M.6
Jia, D.7
Liu, Y.8
Bailey-Wilson, J.E.9
Amos, C.I.10
Pinney, S.M.11
Petersen, G.M.12
De Andrade, M.13
Yang, P.14
Wiest, J.S.15
Fain, P.R.16
Schwartz, A.G.17
Gazdar, A.18
Gaba, C.19
Rothschild, H.20
Mandal, D.21
Kupert, E.22
Seminara, D.23
Viswanathan, A.24
Govindan, R.25
Minna, J.26
Anderson, M.W.27
You, M.28
more..
-
25
-
-
33947287270
-
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib
-
DOI 10.1158/0008-5472.CAN-06-4293
-
Mulloy R, Ferrand A, Kim Y, et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007;67:2325-30. (Pubitemid 46424253)
-
(2007)
Cancer Research
, vol.67
, Issue.5
, pp. 2325-2330
-
-
Mulloy, R.1
Ferrand, A.2
Kim, Y.3
Sordella, R.4
Bell, D.W.5
Haber, D.A.6
Anderson, K.S.7
Settleman, J.8
-
26
-
-
0037674323
-
Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors
-
DOI 10.1074/jbc.M211158200
-
Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003;278:15435-40. (Pubitemid 36799884)
-
(2003)
Journal of Biological Chemistry
, vol.278
, Issue.17
, pp. 15435-15440
-
-
Blencke, S.1
Ullrich, A.2
Daub, H.3
-
27
-
-
68949209102
-
Overview of molecular testing in non-small-cell lung cancer: Mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors
-
John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009;28(Suppl 1):S14-23.
-
(2009)
Oncogene
, vol.28
, Issue.SUPPL. 1
-
-
John, T.1
Liu, G.2
Tsao, M.S.3
-
28
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib
-
DOI 10.1073/pnas.0405220101
-
Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. (Pubitemid 39209661)
-
(2004)
Proceedings of the National Academy of Sciences of the United States of America
, vol.101
, Issue.36
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
Doherty, J.4
Politi, K.5
Sarkaria, I.6
Singh, B.7
Heelan, R.8
Rusch, V.9
Fulton, L.10
Mardis, E.11
Kupfer, D.12
Wilson, R.13
Kris, M.14
Varmus, H.15
-
29
-
-
33846187218
-
Update on epidermal growth factor receptor mutations in non-small cell lung cancer
-
DOI 10.1158/1078-0432.CCR-06-0658
-
Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-41. (Pubitemid 46095394)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.24
, pp. 7232-7241
-
-
Riely, G.J.1
Politi, K.A.2
Miller, V.A.3
Pao, W.4
-
30
-
-
63049132774
-
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
-
Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394-400.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1394-1400
-
-
Inoue, A.1
Kobayashi, K.2
Usui, K.3
-
31
-
-
75249087060
-
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
-
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
-
(2010)
Lancet Oncol
, vol.11
, pp. 121-128
-
-
Mitsudomi, T.1
Morita, S.2
Yatabe, Y.3
-
32
-
-
77953152895
-
A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study
-
Abstract 9 LBA
-
Inoue A, Kobayashi K, Maemondo M, et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. Eur J Cancer Suppl 2009;7:Abstract 9 LBA.
-
(2009)
Eur J Cancer Suppl
, pp. 7
-
-
Inoue, A.1
Kobayashi, K.2
Maemondo, M.3
-
33
-
-
72449160988
-
A randomized phase III study of gefinitib (IRESSATM) versus standard chemotherapy (gemcitabane plus cisplatin) as a first-line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung
-
13th World Conference on Lung Cancer. San Francisco
-
Lee J, Park K, Kim SW. A randomized phase III study of gefinitib (IRESSATM) versus standard chemotherapy (gemcitabane plus cisplatin) as a first-line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung. 13th World Conference on Lung Cancer. San Francisco, J Thorac Oncol 2009;4(Suppl 1):S283-4.
-
(2009)
J Thorac Oncol
, vol.4
, Issue.SUPPL. 1
-
-
Lee, J.1
Park, K.2
Kim, S.W.3
-
34
-
-
33847323129
-
Epidermal growth factor receptor mutations in lung cancer
-
Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 169-181
-
-
Sharma, S.V.1
Bell, D.W.2
Settleman, J.3
-
35
-
-
20044364940
-
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
-
DOI 10.1093/jnci/dji055
-
Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46. (Pubitemid 40425952)
-
(2005)
Journal of the National Cancer Institute
, vol.97
, Issue.5
, pp. 339-346
-
-
Shigematsu, H.1
Lin, L.2
Takahashi, T.3
Nomura, M.4
Suzuki, M.5
Wistuba, I.I.6
Fong, K.M.7
Lee, H.8
Toyooka, S.9
Shimizu, N.10
Fujisawa, T.11
Feng, Z.12
Roth, J.A.13
Herz, J.14
Minna, J.D.15
Gazdar, A.F.16
-
36
-
-
42749085753
-
EGFR FISH versus mutation: Different tests, different end-points
-
Cappuzzo F. EGFR FISH versus mutation: different tests, different end-points. Lung Canc 2008;60:160-5.
-
(2008)
Lung Canc
, vol.60
, pp. 160-165
-
-
Cappuzzo, F.1
-
37
-
-
64249134715
-
Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)
-
Abstract 8038
-
Porta R, Queralt C, Cardenal F, et al. Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p). J Clin Oncol 2008;26:Abstract 8038.
-
(2008)
J Clin Oncol
, pp. 26
-
-
Porta, R.1
Queralt, C.2
Cardenal, F.3
-
38
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
-
39
-
-
67649431893
-
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression
-
Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009;4:e5133.
-
(2009)
PLoS One
, vol.4
-
-
Rosell, R.1
Perez-Roca, L.2
Sanchez, J.J.3
-
40
-
-
20444498630
-
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
-
DOI 10.1093/jnci/dji112
-
Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55. (Pubitemid 40812628)
-
(2005)
Journal of the National Cancer Institute
, vol.97
, Issue.9
, pp. 643-655
-
-
Cappuzzo, F.1
Hirsch, F.R.2
Rossi, E.3
Bartolini, S.4
Ceresoli, G.L.5
Bemis, L.6
Haney, J.7
Witta, S.8
Danenberg, K.9
Domenichini, I.10
Ludovini, V.11
Magrini, E.12
Gregorc, V.13
Doglioni, C.14
Sidoni, A.15
Tonato, M.16
Franklin, W.A.17
Crino, L.18
Bunn Jr., P.A.19
Varella-Garcia, M.20
more..
-
41
-
-
24344459713
-
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
-
DOI 10.1093/annonc/mdi221
-
Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005;16:1081-6. (Pubitemid 41418309)
-
(2005)
Annals of Oncology
, vol.16
, Issue.7
, pp. 1081-1086
-
-
Cortes-Funes, H.1
Gomez, C.2
Rosell, R.3
Valero, P.4
Garcia-Giron, C.5
Velasco, A.6
Izquierdo, A.7
Diz, P.8
Camps, C.9
Castellanos, D.10
Alberola, V.11
Cardenal, F.12
Gonzalez-Larriba, J.L.13
Vieitez, J.M.14
Maeztu, I.15
Sanchez, J.J.16
Queralt, C.17
Mayo, C.18
Mendez, P.19
Moran, T.20
Taron, M.21
more..
-
42
-
-
20244389188
-
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
-
Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2493-2501
-
-
Han, S.W.1
Kim, T.Y.2
Hwang, P.G.3
-
43
-
-
27244451321
-
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
-
Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6829-6837
-
-
Takano, T.1
Ohe, Y.2
Sakamoto, H.3
-
44
-
-
17844390172
-
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
-
Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2556-2568
-
-
Pao, W.1
Miller, V.A.2
-
46
-
-
34347208648
-
Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy
-
DOI 10.1016/j.ccr.2007.06.005, PII S1535610807001742
-
Li D, Shimamura T, Ji H, et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007;12:81-93. (Pubitemid 47001787)
-
(2007)
Cancer Cell
, vol.12
, Issue.1
, pp. 81-93
-
-
Li, D.1
Shimamura, T.2
Ji, H.3
Chen, L.4
Haringsma, H.J.5
McNamara, K.6
Liang, M.-C.7
Perera, S.A.8
Zaghlul, S.9
Borgman, C.L.10
Kubo, S.11
Takahashi, M.12
Sun, Y.13
Chirieac, L.R.14
Padera, R.F.15
Lindeman, N.I.16
Janne, P.A.17
Thomas, R.K.18
Meyerson, M.L.19
Eck, M.J.20
Engelman, J.A.21
Shapiro, G.I.22
Wong, K.-K.23
more..
-
47
-
-
33751292685
-
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
-
DOI 10.1158/1078-0432.CCR-06-1570
-
Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501. (Pubitemid 44799723)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.21
, pp. 6494-6501
-
-
Balak, M.N.1
Gong, Y.2
Riely, G.J.3
Somwar, R.4
Li, A.R.5
Zakowski, M.F.6
Chiang, A.7
Yang, G.8
Ouerfelli, O.9
Kris, M.G.10
Ladanyi, M.11
Miller, V.A.12
Pao, W.13
-
48
-
-
33845265467
-
Impact of EGFR mutations on treatment of non-small cell lung cancer
-
Johnson BE, Jackman D, Janne PA. Impact of EGFR mutations on treatment of non-small cell lung cancer. Canc Chemother Pharmacol 2006;58(Suppl 7):5-9.
-
(2006)
Canc Chemother Pharmacol
, vol.58
, Issue.SUPPL. 7
, pp. 5-9
-
-
Johnson, B.E.1
Jackman, D.2
Janne, P.A.3
-
49
-
-
68949201629
-
Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors
-
Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28(Suppl 1):S24-31.
-
(2009)
Oncogene
, vol.28
, Issue.SUPPL. 1
-
-
Gazdar, A.F.1
-
50
-
-
34250791359
-
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647
-
DOI 10.1158/1078-0432.CCR-06-2590
-
Gendreau SB, Ventura R, Keast P, et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res 2007;13:3713-23. (Pubitemid 46955136)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.12
, pp. 3713-3723
-
-
Gendreau, S.B.1
Ventura, R.2
Keast, P.3
Laird, A.D.4
Yakes, F.M.5
Zhang, W.6
Bentzien, F.7
Cancilla, B.8
Lutman, J.9
Chu, F.10
Jackman, L.11
Shi, Y.12
Yu, P.13
Wang, J.14
Aftab, D.T.15
Jaeger, C.T.16
Meyer, S.M.17
De Costa, A.18
Engell, K.19
Chen, J.20
Martini, J.-F.21
Joly, A.H.22
more..
-
51
-
-
40049099220
-
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
-
DOI 10.1073/pnas.0709662105
-
Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-5. (Pubitemid 351439466)
-
(2008)
Proceedings of the National Academy of Sciences of the United States of America
, vol.105
, Issue.6
, pp. 2070-2075
-
-
Yun, C.-H.1
Mengwasser, K.E.2
Toms, A.V.3
Woo, M.S.4
Greulich, H.5
Wong, K.-K.6
Meyerson, M.7
Eck, M.J.8
-
52
-
-
23844444080
-
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor
-
DOI 10.1158/0008-5472.CAN-05-1346
-
Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005;65:7096-101. (Pubitemid 41161238)
-
(2005)
Cancer Research
, vol.65
, Issue.16
, pp. 7096-7101
-
-
Kobayashi, S.1
Ji, H.2
Yuza, Y.3
Meyerson, M.4
Wong, K.-K.5
Tenen, D.G.6
Halmos, B.7
-
53
-
-
21144439000
-
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
-
Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-70.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 7665-7670
-
-
Kwak, E.L.1
Sordella, R.2
Bell, D.W.3
-
54
-
-
49149118719
-
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
-
Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11.
-
(2008)
Oncogene
, vol.27
, pp. 4702-4711
-
-
Li, D.1
Ambrogio, L.2
Shimamura, T.3
-
55
-
-
23344440655
-
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
-
DOI 10.1073/pnas.0504952102
-
Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 2005;102:11011-16. (Pubitemid 41105984)
-
(2005)
Proceedings of the National Academy of Sciences of the United States of America
, vol.102
, Issue.31
, pp. 11011-11016
-
-
Carter, T.A.1
Wodicka, L.M.2
Shah, N.P.3
Velasco, A.M.4
Fabian, M.A.5
Treiber, D.K.6
Milanov, Z.V.7
Atteridge, C.E.8
Biggs III, W.H.9
Edeen, P.T.10
Floyd, M.11
Ford, J.M.12
Grotzfeld, R.M.13
Herrgard, S.14
Insko, D.E.15
Mehta, S.A.16
Patel, H.K.17
Pao, W.18
Sawyers, C.L.19
Varmus, H.20
Zarrinkar, P.P.21
Lockhart, D.J.22
more..
-
56
-
-
70349684791
-
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer
-
Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119:3000-10.
-
(2009)
J Clin Invest
, vol.119
, pp. 3000-3010
-
-
Regales, L.1
Gong, Y.2
Shen, R.3
-
57
-
-
47949114668
-
Detection of mutations in EGFR in circulating lung-cancer cells
-
Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.
-
(2008)
N Engl J Med
, vol.359
, pp. 366-377
-
-
Maheswaran, S.1
Sequist, L.V.2
Nagrath, S.3
-
58
-
-
33748074447
-
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
-
DOI 10.1158/0008-5472.CAN-06-1951
-
Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006;66:7854-8. (Pubitemid 44299146)
-
(2006)
Cancer Research
, vol.66
, Issue.16
, pp. 7854-7858
-
-
Inukai, M.1
Toyooka, S.2
Ito, S.3
Asano, H.4
Ichihara, S.5
Soh, J.6
Suehisa, H.7
Ouchida, M.8
Aoe, K.9
Aoe, M.10
Kiura, K.11
Shimizu, N.12
Date, H.13
-
59
-
-
46749156706
-
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
-
DOI 10.1172/JC134588
-
Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008;118:2609-19. (Pubitemid 351949788)
-
(2008)
Journal of Clinical Investigation
, vol.118
, Issue.7
, pp. 2609-2619
-
-
Guix, M.1
Faber, A.C.2
Wang, S.E.3
Olivares, M.G.4
Song, Y.5
Qu, S.6
Rinehart, C.7
Seidel, B.8
Yee, D.9
Arteaga, C.L.10
Engelman, J.A.11
-
60
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
DOI 10.1126/science.1141478
-
Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. (Pubitemid 46799492)
-
(2007)
Science
, vol.316
, Issue.5827
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
Song, Y.4
Hyland, C.5
Joon, O.P.6
Lindeman, N.7
Gale, C.-M.8
Zhao, X.9
Christensen, J.10
Kosaka, T.11
Holmes, A.J.12
Rogers, A.M.13
Cappuzzo, F.14
Mok, T.15
Lee, C.16
Johnson, B.E.17
Cantley, L.C.18
Janne, P.A.19
-
61
-
-
33750205340
-
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
-
DOI 10.1038/sj.bjc.6603393, PII 6603393
-
Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004. (Pubitemid 44606825)
-
(2006)
British Journal of Cancer
, vol.95
, Issue.8
, pp. 998-1004
-
-
Asahina, H.1
Yamazaki, K.2
Kinoshita, I.3
Sukoh, N.4
Harada, M.5
Yokouchi, H.6
Ishida, T.7
Ogura, S.8
Kojima, T.9
Okamoto, Y.10
Fujita, Y.11
Dosaka-Akita, H.12
Isobe, H.13
Nishimura, M.14
-
62
-
-
21044445279
-
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer
-
DOI 10.1158/1078-0432.CCR-04-1981
-
Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005;11:3750-7. (Pubitemid 40685592)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.10
, pp. 3750-3757
-
-
Chou, T.-Y.1
Chiu, C.-H.2
Li, L.-H.3
Hsiao, C.-Y.4
Tzen, C.-Y.5
Chang, K.-T.6
Chen, Y.-M.7
Perng, R.-P.8
Tsai, S.-F.9
Tsai, C.-M.10
-
63
-
-
33750700477
-
Erlotinib for frontline treatment of advanced non-small cell lung cancer: A phase II study
-
DOI 10.1158/1078-0432.CCR-06-0260
-
Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006;12:6049-55. (Pubitemid 44703768)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.20 PART 1
, pp. 6049-6055
-
-
Giaccone, G.1
Ruiz, M.G.2
Le, C.T.3
Thatcher, N.4
Smit, E.5
Rodriguez, J.A.6
Janne, P.7
Oulid-Aissa, D.8
Soria, J.-C.9
-
64
-
-
19944426858
-
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan
-
Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 8195-8203
-
-
Huang, S.F.1
Liu, H.P.2
Li, L.H.3
-
65
-
-
33750080906
-
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer
-
PII 0124389420060300000012
-
Kimura H, Kasahara K, Shibata K, et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol 2006;1:260-7. (Pubitemid 47181444)
-
(2006)
Journal of Thoracic Oncology
, vol.1
, Issue.3
, pp. 260-267
-
-
Kimura, H.1
Kasahara, K.2
Shibata, K.3
Sone, T.4
Yoshimoto, A.5
Kita, T.6
Ichikawa, Y.7
Waseda, Y.8
Watanabe, K.9
Shiarasaki, H.10
Ishiura, Y.11
Mizuguchi, M.12
Nakatsumi, Y.13
Kashii, T.14
Kobayashi, M.15
Kunitoh, H.16
Tamura, T.17
Nishio, K.18
Fujimura, M.19
Nakao, S.20
more..
-
66
-
-
33746100318
-
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer
-
DOI 10.1158/1078-0432.CCR-05-2324
-
Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006;12:3915-21. (Pubitemid 44078075)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.13
, pp. 3915-3921
-
-
Kimura, H.1
Kasahara, K.2
Kawaishi, M.3
Kunitoh, H.4
Tamura, T.5
Holloway, B.6
Nishio, K.7
-
67
-
-
84355160803
-
A Phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)
-
Lee CP, Taylor NJ, Attard G, et al. A Phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). MOGA/FRO Annual Scientific Meeting. Sanctuary Cove, Queensland, 2006:9-12.
-
MOGA/FRO Annual Scientific Meeting. Sanctuary Cove, Queensland, 2006
, pp. 9-12
-
-
Lee, C.P.1
Taylor, N.J.2
Attard, G.3
-
68
-
-
20044364933
-
EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
-
DOI 10.1200/JCO.2005.08.043
-
Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-65. (Pubitemid 46224186)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.4
, pp. 857-865
-
-
Marchetti, A.1
Martella, C.2
Felicioni, L.3
Barassi, F.4
Salvatore, S.5
Chella, A.6
Camplese, P.P.7
Iarussi, T.8
Mucilli, F.9
Mezzetti, A.10
Cuccurullo, F.11
Sacco, R.12
Buttitta, F.13
-
69
-
-
20244388126
-
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
-
DOI 10.1200/JCO.2005.00.992
-
Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20. (Pubitemid 47050841)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.11
, pp. 2513-2520
-
-
Mitsudomi, T.1
Kosaka, T.2
Endoh, H.3
Horio, Y.4
Hida, T.5
Mori, S.6
Hatooka, S.7
Shinoda, M.8
Takahashi, T.9
Yatabe, Y.10
-
70
-
-
34548020773
-
Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration
-
DOI 10.1378/chest.07-0095
-
Nakajima T, Yasufuku K, Suzuki M, et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2007;132:597-602. (Pubitemid 47282394)
-
(2007)
Chest
, vol.132
, Issue.2
, pp. 597-602
-
-
Nakajima, T.1
Yasufuku, K.2
Suzuki, M.3
Hiroshima, K.4
Kubo, R.5
Mohammed, S.6
Miyagi, Y.7
Matsukuma, S.8
Sekine, Y.9
Fujisawa, T.10
-
71
-
-
33644845421
-
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study
-
DOI 10.1200/JCO.2005.02.5825
-
Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 2006;24:64-9. (Pubitemid 46630495)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.1
, pp. 64-69
-
-
Niho, S.1
Kubota, K.2
Goto, K.3
Yoh, K.4
Ohmatsu, H.5
Kakinuma, R.6
Saijo, N.7
Nishiwaki, Y.8
-
72
-
-
31544440171
-
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
-
DOI 10.1002/ijc.21458
-
Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006;118:963-9. (Pubitemid 43157672)
-
(2006)
International Journal of Cancer
, vol.118
, Issue.4
, pp. 963-969
-
-
Shih, J.-Y.1
Gow, C.-H.2
Yu, C.-J.3
Yang, C.-H.4
Chang, Y.-L.5
Tsai, M.-F.6
Hsu, Y.-C.7
Chen, K.-Y.8
Su, W.-P.9
Yang, P.-C.10
-
73
-
-
34247619676
-
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy
-
DOI 10.1016/j.lungcan.2007.01.025, PII S0169500207000785
-
Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007;56:383-9. (Pubitemid 46679091)
-
(2007)
Lung Cancer
, vol.56
, Issue.3
, pp. 383-389
-
-
Sunaga, N.1
Tomizawa, Y.2
Yanagitani, N.3
Iijima, H.4
Kaira, K.5
Shimizu, K.6
Tanaka, S.7
Suga, T.8
Hisada, T.9
Ishizuka, T.10
Saito, R.11
Dobashi, K.12
Mori, M.13
-
74
-
-
33845262077
-
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
-
DOI 10.1038/sj.bjc.6603466, PII 6603466
-
Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006;95:1483-9. (Pubitemid 44863350)
-
(2006)
British Journal of Cancer
, vol.95
, Issue.11
, pp. 1483-1489
-
-
Sutani, A.1
Nagai, Y.2
Udagawa, K.3
Uchida, Y.4
Koyama, N.5
Murayama, Y.6
Tanaka, T.7
Miyazawa, H.8
Nagata, M.9
Kanazawa, M.10
Hagiwara, K.11
Kobayashi, K.12
-
75
-
-
33845635125
-
Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers
-
DOI 10.1111/j.1349-7006.2006.00377.x
-
Tanaka T, Nagai Y, Miyazawa H, et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 2007;98:246-52. (Pubitemid 44941878)
-
(2007)
Cancer Science
, vol.98
, Issue.2
, pp. 246-252
-
-
Tanaka, T.1
Nagai, Y.2
Miyazawa, H.3
Koyama, N.4
Matsuoka, S.5
Sutani, A.6
Udagawa, K.7
Murayama, Y.8
Nagata, M.9
Shimizu, Y.10
Ikebuchi, K.11
Kanazawa, M.12
Kobayashi, K.13
Hagiwara, K.14
-
76
-
-
33750057986
-
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
-
DOI 10.1002/cncr.22220
-
Yang CH, Shih JY, Chen KC, et al. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer 2006;107:1873-82. (Pubitemid 44582958)
-
(2006)
Cancer
, vol.107
, Issue.8
, pp. 1873-1882
-
-
Yang, C.-H.1
Shih, J.-Y.2
Chen, K.-C.3
Yu, C.-J.4
Yang, T.-Y.5
Lin, C.-P.6
Su, W.-P.7
Gow, C.-H.8
Hsu, C.9
Chang, G.-C.10
Yang, P.-C.11
-
77
-
-
34249752278
-
Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer
-
PII 0124389420070100000006
-
Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with nonsmall cell lung cancer. J Thorac Oncol 2007;2:22-8. (Pubitemid 47163924)
-
(2007)
Journal of Thoracic Oncology
, vol.2
, Issue.1
, pp. 22-28
-
-
Yoshida, K.1
Yatabe, Y.2
Park, J.Y.3
Shimizu, J.4
Horio, Y.5
Matsuo, K.6
Kosaka, T.7
Mitsudomi, T.8
Hida, T.9
-
78
-
-
33746928318
-
Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer
-
Hsieh MH, Fang YF, Chang WC, et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 2006;53:311-22.
-
(2006)
Lung Cancer
, vol.53
, pp. 311-322
-
-
Hsieh, M.H.1
Fang, Y.F.2
Chang, W.C.3
-
79
-
-
34249845305
-
An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): Maximizing the diagnostic procedure and the use of low-volume lung biopsies
-
DOI 10.1097/01.JTO.0000268671.49378.c2, PII 0124389420070500000005
-
Lim EH, Zhang SL, Yu K, et al. An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximizing the diagnostic procedure and the use of low-volume lung biopsies. J Thorac Oncol 2007;2:387-96. (Pubitemid 47181692)
-
(2007)
Journal of Thoracic Oncology
, vol.2
, Issue.5
, pp. 387-396
-
-
Lim, E.H.1
Zhang, S.-L.2
Yu, K.3
Nga, M.-E.4
Ahmed, D.A.5
Agasthian, T.6
Wong, P.-S.7
Chua, G.-C.8
Wong, D.9
Tan, L.10
Seto, K.-Y.11
Yap, W.-S.12
Low, S.-P.13
Khoo, K.-L.14
Chang, A.15
Ng, A.16
Tan, P.17
-
80
-
-
38049008135
-
Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers
-
Savic S, Tapia C, Grilli B, et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 2008;98:154-60.
-
(2008)
Br J Cancer
, vol.98
, pp. 154-160
-
-
Savic, S.1
Tapia, C.2
Grilli, B.3
-
81
-
-
28844449401
-
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
-
DOI 10.1200/JCO.2005.02.7078
-
Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-92. (Pubitemid 46657411)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.31
, pp. 8081-8092
-
-
Bell, D.W.1
Lynch, T.J.2
Haserlat, S.M.3
Harris, P.L.4
Okimoto, R.A.5
Brannigan, B.W.6
Sgroi, D.C.7
Muir, B.8
Riemenschneider, M.J.9
Iacona, R.B.10
Krebs, A.D.11
Johnson, D.H.12
Giaccone, G.13
Herbst, R.S.14
Manegold, C.15
Fukuoka, M.16
Kris, M.G.17
Baselga, J.18
Ochs, J.S.19
Haber, D.A.20
more..
-
82
-
-
24944497744
-
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
-
Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5900-5909
-
-
Eberhard, D.A.1
Johnson, B.E.2
Amler, L.C.3
-
83
-
-
20144387947
-
Predictors of the response to gefitinib in refractory non-small cell lung cancer
-
Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 2005;11:2244-51.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 2244-2251
-
-
Kim, K.S.1
Jeong, J.Y.2
Kim, Y.C.3
-
84
-
-
50849094202
-
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients
-
Chang JW, Liu HP, Hsieh MH, et al. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients. Lung Cancer 2008;61:328-39.
-
(2008)
Lung Cancer
, vol.61
, pp. 328-339
-
-
Chang, J.W.1
Liu, H.P.2
Hsieh, M.H.3
-
85
-
-
45149084723
-
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
-
Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2442-2449
-
-
Sequist, L.V.1
Martins, R.G.2
Spigel, D.3
-
86
-
-
70350379181
-
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: A population-based prospective study
-
Boldrini L, Ali G, Gisfredi S, et al. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. Oncol Rep 2009;22:683-91.
-
(2009)
Oncol Rep
, vol.22
, pp. 683-691
-
-
Boldrini, L.1
Ali, G.2
Gisfredi, S.3
-
87
-
-
65349165823
-
EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer
-
Smouse JH, Cibas ES, Jänne PA, et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009;117:67-72.
-
(2009)
Cancer
, vol.117
, pp. 67-72
-
-
Smouse, J.H.1
Cibas, E.S.2
Jänne, P.A.3
-
88
-
-
42049099467
-
Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis
-
DOI 10.1136/jcp.2007.051425
-
Smith GD, Chadwick BE, Willmore-Payne C, et al. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol 2008;61:487-93. (Pubitemid 351518232)
-
(2008)
Journal of Clinical Pathology
, vol.61
, Issue.4
, pp. 487-493
-
-
Smith, G.D.1
Chadwick, B.E.2
Willmore-Payne, C.3
Bentz, J.S.4
-
89
-
-
33750302365
-
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib
-
DOI 10.1158/1078-0432.CCR-06-0714
-
Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764-9. (Pubitemid 44629607)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.19
, pp. 5764-5769
-
-
Kosaka, T.1
Yatabe, Y.2
Endoh, H.3
Yoshida, K.4
Hida, T.5
Tsuboi, M.6
Tada, H.7
Kuwano, H.8
Mitsudomi, T.9
-
90
-
-
74249106438
-
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer
-
Mack PC, Holland WS, Burich RA, et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 2009;4:1466-72.
-
(2009)
J Thorac Oncol
, vol.4
, pp. 1466-1472
-
-
Mack, P.C.1
Holland, W.S.2
Burich, R.A.3
-
91
-
-
77958185649
-
Consensus for EGFR mutation testing in non-small cell lung cancer: Results from a European workshop
-
Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010;5:1706-13.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1706-1713
-
-
Pirker, R.1
Herth, F.J.2
Kerr, K.M.3
-
92
-
-
37549002543
-
Isolation of rare circulating tumour cells in cancer patients by microchip technology
-
Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-9.
-
(2007)
Nature
, vol.450
, pp. 1235-1239
-
-
Nagrath, S.1
Sequist, L.V.2
Maheswaran, S.3
-
93
-
-
34248186584
-
Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens
-
DOI 10.1158/1535-7163.MCT-06-0719
-
Daniele L, Macri L, Schena M, et al. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther 2007;6:1223-9. (Pubitemid 46711985)
-
(2007)
Molecular Cancer Therapeutics
, vol.6
, Issue.4
, pp. 1223-1229
-
-
Daniele, L.1
Macri, L.2
Schena, M.3
Dongiovanni, D.4
Bonello, L.5
Armando, E.6
Ciuffreda, L.7
Bertetto, O.8
Bussolati, G.9
Sapino, A.10
-
94
-
-
77951021505
-
Quantitative analysis of tumor in bronchial biopsy specimens
-
Coghlin CL, Smith LJ, Bakar S, et al. Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol 2010;5:448-52.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 448-452
-
-
Coghlin, C.L.1
Smith, L.J.2
Bakar, S.3
-
95
-
-
76149086520
-
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations
-
Garcia-Olivé I, Monsó E, Andreo F, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 2010;35:391-5.
-
(2010)
Eur Respir J
, vol.35
, pp. 391-395
-
-
Garcia-Olivé, I.1
Monsó, E.2
Andreo, F.3
-
96
-
-
73449125505
-
Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis
-
Fassina A, Gazziero A, Zardo D, et al. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. J Clin Pathol 2009;62:1096-102.
-
(2009)
J Clin Pathol
, vol.62
, pp. 1096-1102
-
-
Fassina, A.1
Gazziero, A.2
Zardo, D.3
-
97
-
-
20444477166
-
Global gene expression profiling of circulating tumor cells
-
DOI 10.1158/0008-5472.CAN-04-4330
-
Smirnov DA, Zweitzig DR, Foulk BW, et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005;65:4993-7. (Pubitemid 40827303)
-
(2005)
Cancer Research
, vol.65
, Issue.12
, pp. 4993-4997
-
-
Smirnov, D.A.1
Zweitzig, D.R.2
Foulk, B.W.3
Miller, M.C.4
Doyle, G.V.5
Pienta, K.J.6
Meropol, N.J.7
Weiner, L.M.8
Cohen, S.J.9
Moreno, J.G.10
Connelly, M.C.11
Terstappen, L.W.M.M.12
O'Hara, S.M.13
-
99
-
-
79955879691
-
Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
-
Dufort S, Richard MJ, Lantuejoul S, et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res 2011;30:57.
-
(2011)
J Exp Clin Cancer Res
, vol.30
, pp. 57
-
-
Dufort, S.1
Richard, M.J.2
Lantuejoul, S.3
-
100
-
-
79955820904
-
Benchmarking of mutation diagnostics in clinical lung cancer specimens
-
Querings S, Altmüller J, Ansén S, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 2011;6:e19601.
-
(2011)
PLoS One
, vol.6
-
-
Querings, S.1
Altmüller, J.2
Ansen, S.3
-
101
-
-
33746789922
-
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
-
DOI 10.1200/JCO.2005.05.4692
-
Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6. (Pubitemid 46638887)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.21
, pp. 3340-3346
-
-
Inoue, A.1
Suzuki, T.2
Fukuhara, T.3
Maemondo, M.4
Kimura, Y.5
Morikawa, N.6
Watanabe, H.7
Saijo, Y.8
Nukiwa, T.9
-
102
-
-
23844465454
-
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp
-
DOI 10.1158/0008-5472.CAN-05-0331
-
Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-82. (Pubitemid 41161259)
-
(2005)
Cancer Research
, vol.65
, Issue.16
, pp. 7276-7282
-
-
Nagai, Y.1
Miyazawa, H.2
Huqun3
Tanaka, T.4
Udagawa, K.5
Kato, M.6
Fukuyama, S.7
Yokote, A.8
Kobayashi, K.9
Kanazawa, M.10
Hagiwara, K.11
-
103
-
-
39649116928
-
EGFR tyrosine kinase inhibitors in lung cancer: An evolving story
-
DOI 10.1146/annurev.med.59.090506.202405
-
Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 2008;59:429-42. (Pubitemid 351287947)
-
(2008)
Annual Review of Medicine
, vol.59
, pp. 429-442
-
-
Sequist, L.V.1
Lynch, T.J.2
-
104
-
-
27944499351
-
EGFR and ErbB2 mutation status in Japanese lung cancer patients
-
DOI 10.1002/ijc.21301
-
Sasaki H, Shimizu S, Endo K, et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006;118:180-4. (Pubitemid 41681596)
-
(2006)
International Journal of Cancer
, vol.118
, Issue.1
, pp. 180-184
-
-
Sasaki, H.1
Shimizu, S.2
Endo, K.3
Takada, M.4
Kawahara, M.5
Tanaka, H.6
Matsumura, A.7
Iuchi, K.8
Haneda, H.9
Suzuki, E.10
Kobayashi, Y.11
Yano, M.12
Fujii, Y.13
-
105
-
-
33748592818
-
Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay
-
DOI 10.2353/jmoldx.2006.060030
-
Matsukuma S, Yoshihara M, Kasai F, et al. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn 2006;8:504-12. (Pubitemid 44377934)
-
(2006)
Journal of Molecular Diagnostics
, vol.8
, Issue.4
, pp. 504-512
-
-
Matsukuma, S.1
Yoshihara, M.2
Kasai, F.3
Kato, A.4
Yoshida, A.5
Akaike, M.6
Kobayashi, O.7
Nakayama, H.8
Sakuma, Y.9
Yoshida, T.10
Kameda, Y.11
Tsuchiya, E.12
Miyagi, Y.13
-
106
-
-
58949089105
-
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells
-
Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 2008;3:1224-35.
-
(2008)
J Thorac Oncol
, vol.3
, pp. 1224-1235
-
-
Molina-Vila, M.A.1
Bertran-Alamillo, J.2
Reguart, N.3
-
107
-
-
58949091382
-
An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients
-
Kawada I, Soejima K, Watanabe H, et al. An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. J Thorac Oncol 2008;3:1096-103.
-
(2008)
J Thorac Oncol
, vol.3
, pp. 1096-1103
-
-
Kawada, I.1
Soejima, K.2
Watanabe, H.3
-
108
-
-
32944468710
-
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
-
DOI 10.1158/1078-0432.CCR-05-2047
-
Janne PA, Borras AM, Kuang Y, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006;12:751-8. (Pubitemid 43259854)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.3 I
, pp. 751-758
-
-
Janne, P.A.1
Borras, A.M.2
Kuang, Y.3
Rogers, A.M.4
Joshi, V.A.5
Liyanage, H.6
Lindeman, N.7
Lee, J.C.8
Halmos, B.9
Maher, E.A.10
Distel, R.J.11
Meyerson, M.12
Johnson, B.E.13
-
109
-
-
31544459265
-
Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay
-
DOI 10.1158/1078-0432.CCR-05-0934
-
Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006;12:43-8. (Pubitemid 43166174)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.1
, pp. 43-48
-
-
Asano, H.1
Toyooka, S.2
Tokumo, M.3
Ichimura, K.4
Aoe, K.5
Ito, S.6
Tsukuda, K.7
Ouchida, M.8
Aoe, M.9
Katayama, H.10
Hiraki, A.11
Sugi, K.12
Kiura, K.13
Date, H.14
Shimizu, N.15
-
110
-
-
36448978322
-
Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
-
Kim TY, Han SW, Bang YJ. Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Rev Mol Diagn 2007;7:821-36.
-
(2007)
Expert Rev Mol Diagn
, vol.7
, pp. 821-836
-
-
Kim, T.Y.1
Han, S.W.2
Bang, Y.J.3
-
111
-
-
51049110952
-
Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer
-
Fukui T, Ohe Y, Tsuta K, et al. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4751-7.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4751-4757
-
-
Fukui, T.1
Ohe, Y.2
Tsuta, K.3
-
112
-
-
33749340253
-
Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis
-
DOI 10.1309/N5PQ-NGW2-QKMX-09X7
-
Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006;126:608-15. (Pubitemid 44498512)
-
(2006)
American Journal of Clinical Pathology
, vol.126
, Issue.4
, pp. 608-615
-
-
Nomoto, K.1
Tsuta, K.2
Takano, T.3
Fukui, T.4
Yokozawa, K.5
Sakamoto, H.6
Yoshida, T.7
Maeshima, A.M.8
Shibata, T.9
Furuta, K.10
Ohe, Y.11
Matsuno, Y.12
-
113
-
-
63449103435
-
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients
-
Yung TK, Chan KC, Mok TS, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009;15:2076-84.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2076-2084
-
-
Yung, T.K.1
Chan, K.C.2
Mok, T.S.3
-
114
-
-
84355164607
-
Direct detection of rare circulating tumor cells in blood by castPCR
-
Tan R, Brzoska P. Direct detection of rare circulating tumor cells in blood by castPCR. J Biomol Tech 2010;21(3 Suppl):S30.
-
(2010)
J Biomol Tech
, vol.21
, Issue.3 SUPPL.
-
-
Tan, R.1
Brzoska, P.2
-
115
-
-
65649128973
-
Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer
-
Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009;15:3023-8.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3023-3028
-
-
Yu, J.1
Kane, S.2
Wu, J.3
-
116
-
-
77958198161
-
Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: Immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations
-
Kato Y, Peled N, Wynes MW, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010;5:1551-8.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1551-1558
-
-
Kato, Y.1
Peled, N.2
Wynes, M.W.3
|